The Department of Health has today [6 July] published the Q1 2017 PPRS data showing that the pharmaceutical industry has paid £94 million during the first quarter (Q1) of 2017 under the 2014 Pharmaceutical Price Regulation Scheme (PPRS).
It has been a lively week for the global media debate on the price of medicines. Here in the UK, The Guardian has published, today, a piece claiming that overly ‘exorbitant drug prices’ are the reason cancer patients are denied access to some medicines. It cites an advance copy of new research that...
Public Health England’s National Cancer Intelligence Network (NCIN) recently published their ‘Kidney Cancer Survival Report’, which shows that kidney cancer survival has improved in the last 20 years (1).
Medicines play a crucial role in maintaining health, preventing illness, managing chronic conditions and curing disease. However, there is a growing body of evidence that shows us that there is an urgent need to get the fundamentals of medicines use right.
The concept of maintaining a “stiff upper lip”—not showing any emotion—is something that many people think characterises the British. It is an antiquated stereotype that has left us with a reputation for being reserved and reluctant to express our feelings.
The National Health Service is our most treasured of national institutions and the relationship it enjoys with the life sciences industry has been, and remains, a very strong one.
Read the latest decisions of the 2009 Pharmaceutical Price Regulation Scheme Dispute (PPRS) Resolution Panel
We are delighted to announce our second one day ABPI Masterclass on PPRS, taking place on 10 June at the Royal Society, SW1.
We are delighted to announce our first one day ABPI Masterclass on PPRS, taking place on 16 May at the Royal Society, SW1.
What did the 11th Report to Parliament on the Pharmaceutical Price Regulation Scheme (PPRS) find? ABPI CEO Stephen Whitehead explores the issues.